Are there regional variations in the presentation of childhood leukemia?

Autores

  • Klerize de Souza Silva Universidade Federal do Rio Grande do Sul
  • Ciliana Rechenmacher
  • Rahuany Velleda de Morais Hospital de Clínicas de Porto Alegre
  • Mariana Bohns Michalowski
  • Liane Esteves Daudt

Palavras-chave:

childhood ALL, risk factors, immunophenotyping, minimal residual disease.

Resumo

Introduction: Treatment of childhood acute lymphoblastic leukemia (ALL) is based
on risk stratification. This study aimed to assess the agreement between risk group
classifications in the different childhood ALL treatment protocols used in a referral
hospital in southern Brazil.
Methods: We retrospectively reviewed the medical records of patients aged 1 to
18 years with B-cell ALL treated at a hospital from January 2013 to April 2017. Agreement
between risk classifications was assessed by the kappa coefficient.
Results: Seventy-five patients were analyzed. There was poor agreement between
risk stratification by GBTLI 2009 and BFM 95 protocols (kappa=0.22; p = 0.003) and
by GBTLI 2009 and IC-BFM 2002 protocols (kappa=0.24; p = 0.002). Risk group
distribution was 13.3% for low risk, 32.0% for intermediate risk, and 54.7% for high
risk based on stratification by the GBTLI 2009 protocol, and 28.0% for low risk, 42.7%
for intermediate risk, and 29.3% for high risk based on stratification by the IC-BFM
2002 protocol. Overall survival was 68.6%.
Conclusion: This study provides numerous points to ponder about the treatment
of leukemia in Brazil. The percentage of patients classified as high risk in our
sample was higher than that reported in the international literature. This difference,
however, had no impact on overall survival, which was shorter than that reported
in the international literature.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2021-10-05

Como Citar

1.
Silva K de S, Rechenmacher C, de Morais RV, Michalowski MB, Daudt LE. Are there regional variations in the presentation of childhood leukemia?. Clin Biomed Res [Internet]. 5º de outubro de 2021 [citado 28º de março de 2024];41(3). Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/108722

Artigos mais lidos pelo mesmo(s) autor(es)